Comparative Pharmacology
Head-to-head clinical analysis: SULFOSE versus SULTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFOSE versus SULTRIN.
SULFOSE vs SULTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic